Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors

The biosynthetic pathway of the CoQ polyisoprenoid side chain, starting from acetyl-CoA and proceeding through mevalonate and isopentenylpyrophosphate, is the same as that of cholesterol. We performed this study to evaluate whether vastatins (hypocholesterolemic drugs that inhibit HMG-CoA reductase)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular aspects of medicine 1994, Vol.15 Suppl, p.s187-s193
Hauptverfasser:	Bargossi, A M, Grossi, G, Fiorella, P L, Gaddi, A, Di Giulio, R, Battino, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Apolipoproteins B - blood Apoproteins - blood Blood Platelets - chemistry Cholesterol - blood Coenzymes Cross-Over Studies Electrocardiography Hemodynamics - drug effects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - drug therapy Lipoproteins - blood Lovastatin - analogs & derivatives Lovastatin - pharmacology Lovastatin - therapeutic use Myoglobin - blood Oxidation-Reduction Simvastatin Treatment Outcome Triglycerides - blood Ubiquinone - analogs & derivatives Ubiquinone - blood Ubiquinone - chemistry Ubiquinone - pharmacology Ubiquinone - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!